MERTK抗体;MERTK Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using MERTK mouse mAb against HepG2 (1), and PANC-1 (2) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using MERTK mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of bel-7402 cells using MERTK mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of HepG2 cells using MERTK mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of U937 cells using MERTK mouse mAb (green) and negative control (red).    

  
  

MERTK (MER Proto-Oncogene, Tyrosine Kinase) is a receptor tyrosine kinase belonging to the TAM family (TYRO3. AXL, MERTK), which regulates critical cellular processes such as proliferation, survival, migration, and immune modulation. It is activated by binding to ligands like Gas6 and Protein S, initiating downstream signaling pathways. MERTK is widely expressed in epithelial, immune, and neural cells, playing roles in tissue homeostasis, phagocytosis, and resolution of inflammation. Dysregulation of MERTK is implicated in pathologies, including cancer, autoimmune diseases, and retinal disorders.

In cancer, MERTK overexpression promotes tumor survival, immune evasion, and therapy resistance by suppressing anti-tumor immunity. This has spurred interest in developing MERTK-targeted therapies, such as monoclonal antibodies. MERTK antibodies block ligand binding or receptor activation, inhibiting oncogenic signaling and enhancing immune recognition. Preclinical studies show efficacy in solid tumors (e.g., melanoma, lung cancer) and hematologic malignancies.

MERTK antibodies also hold promise in treating age-related macular degeneration (AMD) by modulating retinal pigment epithelium phagocytosis. Additionally, they are explored in autoimmune contexts to counteract excessive TAM-mediated immunosuppression. Challenges include optimizing selectivity to avoid off-target effects and overcoming resistance mechanisms. Several MERTK-targeting antibodies are in early-stage clinical trials, highlighting their therapeutic potential across diverse diseases.